Victory Capital Management Inc Allakos Inc. Transaction History

Victory Capital Management Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$8.55 - $111.89 $32,558 - $426,077	-3,808 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$76.53 - $110.43 $179,233 - $258,627	-2,342 Reduced 38.08%	3,808 $403,000
Q2 2021 Aug 03, 2021	SELL	$85.37 - $114.1 $214,961 - $287,303	-2,518 Reduced 29.05%	6,150 $525,000
Q1 2021 May 04, 2021	BUY	$109.73 - $153.66 $24,469 - $34,266	223 Added 2.64%	8,668 $995,000
Q4 2020 Feb 01, 2021	BUY	$79.58 - $152.45 $39,949 - $76,529	502 Added 6.32%	8,445 $1.18 Million
Q3 2020 Nov 09, 2020	SELL	$66.43 - $90.99 $52,081 - $71,336	-784 Reduced 8.98%	7,943 $647,000
Q2 2020 Aug 07, 2020	SELL	$44.04 - $80.69 $3.45 Million - $6.31 Million	-78,253 Reduced 89.97%	8,727 $627,000
Q1 2020 May 04, 2020	BUY	$44.49 - $93.39 $444 - $933	10 Added 0.01%	86,980 $3.87 Million
Q4 2019 Feb 06, 2020	BUY	$66.49 - $137.73 $132,913 - $275,322	1,999 Added 2.35%	86,970 $8.29 Million
Q4 2019 Feb 04, 2020	SELL	$66.49 - $137.73 $23.7 Million - $49 Million	-355,846 Reduced 80.72%	84,971 $6.14 Million
Q3 2019 Nov 12, 2019	BUY	$31.0 - $89.73 $11.9 Million - $34.4 Million	383,007 Added 662.53%	440,817 $34.7 Million
Q2 2019 Aug 15, 2019	BUY	$36.0 - $44.73 $441,000 - $547,942	12,250 Added 26.89%	57,810 $2.51 Million
Q1 2019 May 03, 2019	BUY	$33.79 - $51.99 $701,480 - $1.08 Million	20,760 Added 83.71%	45,560 $1.85 Million
Q4 2018 Feb 05, 2019	SELL	$31.59 - $62.65 $171,217 - $339,563	-5,420 Reduced 17.94%	24,800 $1.3 Million
Q3 2018 Nov 01, 2018	BUY	$31.25 - $47.64 $944,375 - $1.44 Million	30,220 New	30,220 $1.36 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.